Christina Yap, PhD, The Institute of Cancer Research, Sutton, UK, comments on the ongoing evolution of early phase trial designs. Many of these trials, which are aiming to find a recommended dosage for treatments now consider multiple outcomes in their results. Similarly, complex trial designs such as platform trials where treatment arms can be added or dropped through the duration of the trial to answer multiple objectives, are becoming more commonplace. Professor Yap discusses the extra consideration needed when following reporting guidelines to ensure full transparency. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
